Literature DB >> 15086192

Elevation of cytokines in peritoneal fluid and blood in patients with liver cirrhosis.

A S Eriksson1, C Gretzer, S Wallerstedt.   

Abstract

BACKGROUND/AIMS: Liver cirrhosis, described as the endstage of a necroinflammatory process, is often accompanied by ascites formation. The rationale for this study was the hypothesis that patients with liver cirrhosis have a low-grade chronic inflammatory response, which leads to an increased amount of proinflammatory cytokines accumulated in ascites. Twenty-five patients with liver cirrhosis complicated by ascites and twelve healthy volunteers were prospectively included in the study.
METHODOLOGY: Ascites and blood samples from the patients were obtained for analysis of inflammatory cytokines using enzyme-linked immunosorbent assay methodology. Blood samples were taken from the healthy volunteers to obtain reference values.
RESULTS: Plasma and ascites concentrations of interleukin-1alpha, interleukin-6, and tumor necrosis factor-alpha were significantly elevated in the patients compared with plasma levels in the group of healthy controls. Significant elevation of interleukin-10 concentrations was found in ascites but not in plasma in the patients. There was no significant difference in interleukin-10 levels between patient and control plasma.
CONCLUSIONS: The findings suggest that elevated cytokine concentrations in ascites and serum could perpetuate an inflammatory reaction that may be a source of preservation of an ongoing systemic inflammatory reaction. This may contribute to the maintenance, and even progress, of the liver dysfunction, leading to exaggerated ascites development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15086192

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

1.  Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes.

Authors:  Jian Yang; Chunshu Hao; Dongfang Yang; Deshi Shi; Xiulong Song; Xiaofei Luan; Gang Hu; Bingfang Yan
Journal:  Toxicol Lett       Date:  2010-06-09       Impact factor: 4.372

2.  DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes.

Authors:  Mao Zhao; Luan Xiaofei; Cao Gang; Liu Wei; Xiong Jing; Hu Gang; Chen Ruini; Ning Rui; Shang Wei; Yang Jian; Yan Bingfang
Journal:  Biochem Pharmacol       Date:  2012-06-21       Impact factor: 5.858

3.  Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin.

Authors:  Dongfang Yang; Robin E Pearce; Xiliang Wang; Roger Gaedigk; Yu-Jui Yvonne Wan; Bingfang Yan
Journal:  Biochem Pharmacol       Date:  2008-10-15       Impact factor: 5.858

4.  Increased intestinal macromolecular permeability and urine nitrite excretion associated with liver cirrhosis with ascites.

Authors:  Soong Lee; Seung-Cheol Son; Moon-Jong Han; Woo-Jin Kim; Soo-Hyun Kim; Hye-Ran Kim; Woo-Kyu Jeon; Ki-Hong Park; Myung-Geun Shin
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

Review 5.  Fatigue in liver disease: pathophysiology and clinical management.

Authors:  Mark G Swain
Journal:  Can J Gastroenterol       Date:  2006-03       Impact factor: 3.522

6.  Exercise might prevent cirrhosis in overweight and obese adults.

Authors:  Cheng-Feng Jan; Oswald Ndi Nfor; Jing-Yang Huang; Shu-Yi Hsu; Pei-Chieh Ko; Min-Chen Wu; Chien-Chang Ho; Yung-Po Liaw
Journal:  Liver Int       Date:  2017-09-06       Impact factor: 5.828

7.  PROUD: effects of preoperative long-term immunonutrition in patients listed for liver transplantation.

Authors:  Arash Nickkholgh; Heinz Schneider; Jens Encke; Markus W Büchler; Jan Schmidt; Peter Schemmer
Journal:  Trials       Date:  2007-08-27       Impact factor: 2.279

Review 8.  Hypothalamus-Pituitary-Adrenal Dysfunction in Cholestatic Liver Disease.

Authors:  Anca D Petrescu; Jessica Kain; Victoria Liere; Trace Heavener; Sharon DeMorrow
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-12       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.